Ahmad Ubharay

Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years

S. Goud, S. More, Ajay Singh, 2024, Cancer Research, Statistics, and Treatment.

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India

V. Noronha, N. Purandare, Atul Tiwari, 2024, South Asian Journal of Cancer.